Rigosertib


Rigosertib is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics. Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.
Its geometrical isomer -ON 01910·Na has less cytotoxicity on cancer cells.

Mechanism

Rigosertib is a microtubule-destabilizing agent.